US 11,052,089 B2
Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype
David A. Cheresh, La Jolla, CA (US); Maricel Gozo, La Jolla, CA (US); Mayra Yebra, La Jolla, CA (US); and Laetitia Seguin, La Jolla, CA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Appl. No. 15/537,403
Filed by The Regents of the University of California, Oakland, CA (US)
PCT Filed Dec. 18, 2015, PCT No. PCT/US2015/066762
§ 371(c)(1), (2) Date Jun. 16, 2017,
PCT Pub. No. WO2016/100858, PCT Pub. Date Jun. 23, 2016.
Claims priority of provisional application 62/148,136, filed on Apr. 15, 2015.
Claims priority of provisional application 62/094,020, filed on Dec. 18, 2014.
Prior Publication US 2018/0000821 A1, Jan. 4, 2018
Int. Cl. A61P 35/00 (2006.01); A61P 35/04 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); G01N 33/574 (2006.01); A61K 45/06 (2006.01); A61K 31/454 (2006.01); A61K 31/444 (2006.01)
CPC A61K 31/517 (2013.01) [A61K 31/444 (2013.01); A61K 31/454 (2013.01); A61K 45/06 (2013.01); G01N 33/574 (2013.01)] 5 Claims
 
1. A method for treating or ameliorating lung cancer or a lung tumor in an individual in need thereof by slowing or preventing the phenotypic conversion of a lung cancer cell or lung tumor cell that does not express an alpha-V (α-V)/beta-3 (β3) polypeptide dimer to a lung cancer stem cell or lung tumor stem cell phenotype that expresses an alpha-V (α-V)/beta-3 (β3) polypeptide dimer in the individual;
the method comprising:
(a) identifying the individual has lung cancer or a lung tumor that does not express a cell surface alpha-V (α-V)/beta-3 (β3) polypeptide dimer, and
(b) administering to the identified individual a pharmaceutical composition comprising GSKJ4 to inhibit or deplete a histone acetyl transferase activity,
thereby slowing or preventing the phenotypic conversion of the lung cancer cell or lung tumor cell to the lung cancer stem cell or a lung tumor stem cell.